Phoenix SENOLYTIX is a longevity company using advanced technologies to develop novel gene therapies targeting the fundamental mechanisms of aging. Its lead program, utilizing its proprietary purposeful cell elimination technology, ApoptiCIDe™, targets senescent cells for elimination, restoring the youthful balance of aged or “senescent” and young cells throughout the organs of the body.  Our leadership team were the founders of Bellicum Pharmaceuticals, the first CAR-T cell company, in 2004.  Inventors of CaspaCIDe™ at Bellicum, the most effective cell therapy safety switch validated in humans, they have now repurposed this technology, previously established as both safe and effective senolytic therapy in the p16Ink4a-ATTAC mouse model of genomic ablation of senescent cells, now as ApoptiCIDe™ to target senescent cells for non-inflammatory, apoptotic elimination, among other uses, in patients.  By targeting senescent cells for elimination, we have a unique opportunity to intervene in the aging process in ways that were once thought impossible.

Phoenix SENOLYTIX, Inc.

Org chart

Teams

Offices